CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.

Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther. 2018;33(2):178–203.

pubmed: 29594964 pmcid: 5880864 doi: 10.1007/s12928-018-0516-y

Ozaki Y, Hara H, Onuma Y, Katagiri Y, Amano T, Kobayashi Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovasc Interv Ther. 2022;37(1):1–34.

pubmed: 35018605 pmcid: 8789715 doi: 10.1007/s12928-021-00829-9

Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.

pubmed: 37622654 doi: 10.1093/eurheartj/ehad191

Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New Engl J Med. 1999;341(9):625–34.

pubmed: 10460813 doi: 10.1056/NEJM199908263410901

Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet (London, Engl). 2002;360(9336):825–9.

doi: 10.1016/S0140-6736(02)09963-4

Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J. 2003;24(1):94–104.

pubmed: 12559941 doi: 10.1016/S0195-668X(02)00468-2

Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation. 2003;108(23):2851–6.

pubmed: 14623806 doi: 10.1161/01.CIR.0000103122.10021.F2

Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002;288(17):2130–5.

pubmed: 12413372 doi: 10.1001/jama.288.17.2130

Zijlstra F, Beukema WP, van’t Hof AW, Liem A, Reiffers S, Hoorntje JC, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol. 1997;29(5):908–12.

pubmed: 9120174 doi: 10.1016/S0735-1097(97)00018-1

Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328(10):680–4.

pubmed: 8433726 doi: 10.1056/NEJM199303113281002

Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J. 2000;21(10):823–31.

pubmed: 10781354 doi: 10.1053/euhj.1999.1993

de Boer MJ, Ottervanger JP, van’t Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol. 2002;39(11):1723–8.

pubmed: 12039482 doi: 10.1016/S0735-1097(02)01878-8

Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O’Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. New Engl J Med. 1993;328(10):673–9.

pubmed: 8433725 doi: 10.1056/NEJM199303113281001

Ribichini F, Steffenino G, Dellavalle A, Ferrero V, Vado A, Feola M, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol. 1998;32(6):1687–94.

pubmed: 9822097 doi: 10.1016/S0735-1097(98)00446-X

Garcia E, Elizaga J, Perez-Castellano N, Serrano JA, Soriano J, Abeytua M, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol. 1999;33(3):605–11.

pubmed: 10080458 doi: 10.1016/S0735-1097(98)00644-5

Investigators GUoStOOCAiACSGIAS. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. New Engl J Med. 1997;336(23):1621–8.

doi: 10.1056/NEJM199706053362301

Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. New Engl J Med. 2000;343(6):385–91.

pubmed: 10933737 doi: 10.1056/NEJM200008103430602

Vermeer F, Oude Ophuis AJ, van den Berg EJ, Brunninkhuis LG, Werter CJ, Boehmer AG, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart (Br Card Soc). 1999;82(4):426–31.

Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet (Lond, Engl). 2002;359(9310):920–5.

doi: 10.1016/S0140-6736(02)08022-4

Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287(15):1943–51.

pubmed: 11960536 doi: 10.1001/jama.287.15.1943

Grines CL, Westerhausen DR Jr, Grines LL, Hanlon JT, Logemann TL, Niemela M, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol. 2002;39(11):1713–9.

pubmed: 12039480 doi: 10.1016/S0735-1097(02)01870-3

Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349(8):733–42.

pubmed: 12930925 doi: 10.1056/NEJMoa025142

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.

pubmed: 28886621 doi: 10.1093/eurheartj/ehx393

Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367.

pubmed: 32860058 doi: 10.1093/eurheartj/ehaa575

Kwon O, Park DW. Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in east Asian populations. JACC Asia. 2022;2(1):1–18.

pubmed: 36340250 pmcid: 9627845 doi: 10.1016/j.jacasi.2021.12.005

Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23.

pubmed: 23698643 pmcid: 3748366 doi: 10.1038/clpt.2013.105

Moller JE, Engstrom T, Jensen LO, Eiskjaer H, Mangner N, Polzin A, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390(15):1382–93.

pubmed: 38587239 doi: 10.1056/NEJMoa2312572

Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.

pubmed: 22922416 doi: 10.1093/eurheartj/ehs215

Nishio R, Ogita M, Suwa S, Nakao K, Ozaki Y, Kimura K, et al. Shorter door-to-balloon time, better long-term clinical outcomes in ST-segment elevation myocardial infarction patients: J-MINUET substudy. J Cardiol. 2023;81(6):564–70.

pubmed: 36736534 doi: 10.1016/j.jjcc.2023.01.008

Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, et al. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J. 2013;77(4):934–43.

pubmed: 23502993 doi: 10.1253/circj.CJ-13-0174

Miyachi H, Yamamoto T, Takayama M, Miyauchi K, Yamasaki M, Tanaka H, et al. 10-Year temporal trends of in-hospital mortality and emergency percutaneous coronary intervention for acute myocardial infarction. JACC Asia. 2022;2(6):677–88.

pubmed: 36444314 pmcid: 9700040 doi: 10.1016/j.jacasi.2022.06.005

Fukui K, Takahashi J, Hao K, Honda S, Nishihira K, Kojima S, et al. Disparity of performance measure by door-to-balloon time between a rural and urban area for management of patients with ST-segment elevation myocardial infarction—insights from the nationwide Japan acute myocardial infarction registry. Circ J. 2023;87(5):648–56.

pubmed: 36464277 doi: 10.1253/circj.CJ-22-0454

Arai R, Okumura Y, Murata N, Fukamachi D, Honda S, Nishihira K, et al. Prevalence and impact of polyvascular disease in patients with acute myocardial infarction in the contemporary era of percutaneous coronary intervention—insights from the Japan Acute Myocardial Infarction Registry (JAMIR). Circ J. 2024;88(6):911–20.

pubmed: 38008436 doi: 10.1253/circj.CJ-23-0477

Ishii M, Tsujita K, Okamoto H, Koto S, Nishi T, Nakai M, et al. Resources for cardiovascular healthcare associated with 30-day mortality in acute myocardial infarction with cardiogenic shock. Eur Heart J Open. 2022;2(1):oeab047.

pubmed: 35919660 doi: 10.1093/ehjopen/oeab047

Anzai F, Yoshihisa A, Takeishi R, Hotsuki Y, Sato Y, Sumita Y, et al. Acute myocardial infarction caused by Kawasaki disease requires more intensive therapy: Insights from the Japanese registry of all cardiac and vascular diseases-diagnosis procedure combination. Catheter Cardiovasc Interv. 2022;100(7):1173–81.

pubmed: 36316815 doi: 10.1002/ccd.30457

Nishi T, Ishii M, Tsujita K, Okamoto H, Koto S, Nakai M, et al. Outcomes of venoarterial extracorporeal membrane oxygenation plus intra-aortic balloon pumping for treatment of acute myocardial infarction complicated by cardiogenic shock. J Am Heart Assoc. 2022;11(7): e023713.

pubmed: 35377180 pmcid: 9075437 doi: 10.1161/JAHA.121.023713

Yamaji K, Kohsaka S, Inohara T, Numasawa Y, Ando H, Wada H, et al. Percutaneous coronary intervention during the COVID-19 pandemic in Japan: Insights from the nationwide registration data. Lancet Reg Health West Pac. 2022;22: 100434.

pubmed: 35330940 pmcid: 8939342

Inohara T, Kohsaka S, Yamaji K, Iida O, Shinke T, Sakakura K, et al. Use of thrombus aspiration for patients with acute coronary syndrome: insights from the nationwide J-PCI registry. J Am Heart Assoc. 2022;11(16): e025728.

pubmed: 35946472 pmcid: 9496318 doi: 10.1161/JAHA.122.025728

Ando H, Yamaji K, Kohsaka S, Ishii H, Sakakura K, Goto R, et al. Clinical presentation and in-hospital outcomes of acute myocardial infarction in young patients: Japanese nationwide registry. JACC Asia. 2022;2(5):574–85.

pubmed: 36518720 pmcid: 9743453 doi: 10.1016/j.jacasi.2022.03.013

Saito Y, Inohara T, Kohsaka S, Ando H, Ishii H, Yamaji K, et al. Volume-outcome relations of percutaneous coronary intervention in patients presenting with acute myocardial infarction (from the J-PCI Registry). Am J Cardiol. 2023;192:182–9.

pubmed: 36812702 doi: 10.1016/j.amjcard.2023.01.027

Saito Y, Inohara T, Kohsaka S, Wada H, Takamisawa I, Yamaji K, et al. Characteristics and outcomes of patients with no standard modifiable risk factors undergoing primary revascularization for acute myocardial infarction: insights from the nationwide Japanese percutaneous coronary intervention registry. Am Heart J. 2023;258:69–76.

pubmed: 36642224 doi: 10.1016/j.ahj.2023.01.009

Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):381–9.

pubmed: 32679111 pmcid: 7429983 doi: 10.1016/S0140-6736(20)31356-8

Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020;383(7):691–3.

pubmed: 32427432 doi: 10.1056/NEJMc2015630

Bouisset F, Gerbaud E, Bataille V, Coste P, Puymirat E, Belle L, et al. Percutaneous myocardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol. 2021;78(13):1291–305.

pubmed: 34556314 doi: 10.1016/j.jacc.2021.07.039

Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355(23):2395–407.

pubmed: 17105759 pmcid: 1995554 doi: 10.1056/NEJMoa066139

Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55(22):2435–45.

pubmed: 20359842 doi: 10.1016/j.jacc.2010.03.007

Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome. Circulation. 2018;138(24):2741–50.

pubmed: 30565996 doi: 10.1161/CIRCULATIONAHA.118.037152

Hashimoto Y, Ozaki Y, Kan S, Nakao K, Kimura K, Ako J, et al. Impact of chronic kidney disease on in-hospital and 3-year clinical outcomes in patients with acute myocardial infarction treated by contemporary percutaneous coronary intervention and optimal medical therapy—insights from the J-MINUET study. Circ J. 2021;85(10):1710–8.

pubmed: 34078824 doi: 10.1253/circj.CJ-20-1115

Komiyama K, Nakamura M, Tanabe K, Niikura H, Fujimoto H, Oikawa K, et al. In-hospital mortality analysis of Japanese patients with acute coronary syndrome using the Tokyo CCU Network database: applicability of the GRACE risk score. J Cardiol. 2017;71(3):251–8.

pubmed: 29102289 doi: 10.1016/j.jjcc.2017.09.006

Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380(15):1397–407.

pubmed: 30883057 doi: 10.1056/NEJMoa1816897

Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen MM, et al. Coronary angiography after cardiac arrest without ST segment elevation: one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol. 2020;5(12):1–8.

pmcid: 7489423 doi: 10.1001/jamacardio.2020.3670

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

pubmed: 17982182 doi: 10.1056/NEJMoa0706482

Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78(7):1684–92.

pubmed: 24759796 doi: 10.1253/circj.CJ-13-1482

Sahlen A, Varenhorst C, Lagerqvist B, Renlund H, Omerovic E, Erlinge D, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37(44):3335–42.

pubmed: 27436867 doi: 10.1093/eurheartj/ehw284

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

pubmed: 19717846 doi: 10.1056/NEJMoa0904327

Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–34.

pubmed: 31475799 doi: 10.1056/NEJMoa1908973

Masuda S, Muramatsu T, Ishibashi Y, Kozuma K, Tanabe K, Nakatani S, et al. Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study. AsiaIntervention. 2023;9(1):39–48.

pubmed: 36936091 pmcid: 10018289 doi: 10.4244/AIJ-D-22-00033

Muramatsu T, Masuda S, Kotoku N, Kozuma K, Kawashima H, Ishibashi Y, et al. Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum–chromium everolimus eluting stent for Japanese patients with chronic coronary syndrome (ASET-JAPAN). Circ J. 2023;87(6):857–65.

pubmed: 36908118 doi: 10.1253/circj.CJ-23-0051

Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation. 2024;149(8):585–600.

pubmed: 37994553 doi: 10.1161/CIRCULATIONAHA.123.066720

Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet (Lond, Engl). 2011;378(9792):693–703.

doi: 10.1016/S0140-6736(11)60876-3

Silvain J, Beygui F, Barthelemy O, Pollack C Jr, Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ (Clin Res Ed). 2012;344: e553.

doi: 10.1136/bmj.e553

Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care. 2016;5(3):253–62.

pubmed: 25746943 doi: 10.1177/2048872615572599

Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015;373(11):997–1009.

pubmed: 26324049 doi: 10.1056/NEJMoa1507854

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–30.

pubmed: 18499566 doi: 10.1056/NEJMoa0708191

Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359(7):688–96.

pubmed: 18703471 doi: 10.1056/NEJMoa0802944

Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, et al. Bleeding after percutaneous coronary intervention with bivalirudin or unfractionated heparin and one-year mortality. Am J Cardiol. 2010;105(2):163–7.

pubmed: 20102912 doi: 10.1016/j.amjcard.2009.08.668

Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017;377(12):1132–42.

pubmed: 28844201 doi: 10.1056/NEJMoa1706443

Nakagawa Y, Nobuyoshi M, Yamaguchi T, Meguro T, Yokoi H, Kimura T, et al. Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circ J. 2009;73(1):145–51.

pubmed: 19023152 doi: 10.1253/circj.CJ-08-0560

Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (radial versus femoral randomized investigation in ST-elevation acute coronary syndrome) study. J Am Coll Cardiol. 2012;60(24):2481–9.

pubmed: 22858390 doi: 10.1016/j.jacc.2012.06.017

Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (Lond, Engl). 2011;377(9775):1409–20.

doi: 10.1016/S0140-6736(11)60404-2

Vranckx P, Frigoli E, Rothenbuhler M, Tomassini F, Garducci S, Ando G, et al. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Eur Heart J. 2017;38(14):1069–80.

pubmed: 28329389 doi: 10.1093/eurheartj/ehx048

Saito S, Tanaka S, Hiroe Y, Miyashita Y, Takahashi S, Tanaka K, et al. Comparative study on transradial approach vs. transfemoral approach in primary stent implantation for patients with acute myocardial infarction: results of the test for myocardial infarction by prospective unicenter randomization for access sites (TEMPURA) trial. Catheter Cardiovasc Intervent. 2003;59(1):26–33.

doi: 10.1002/ccd.10493

Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nishikawa M, et al. Impact of arterial access route on bleeding complications in Japanese patients undergoing percutaneous coronary intervention—insight from the PRASFIT trial. Circ J. 2015;79(9):1928–37.

pubmed: 26040334 doi: 10.1253/circj.CJ-15-0276

Yamashita Y, Shiomi H, Morimoto T, Yaku H, Kaji S, Furukawa Y, et al. Transradial versus transfemoral approach in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction: insight from the CREDO-Kyoto AMI registry. Heart Vessels. 2017;32(12):1448–57.

pubmed: 28698995 doi: 10.1007/s00380-017-1021-4

Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini. Greece Eur Heart J. 2004;25(12):1077–82.

pubmed: 15191780 doi: 10.1016/j.ehj.2004.01.002

Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, Specchia G, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82(3):269–72.

pubmed: 10455073 pmcid: 1729173 doi: 10.1136/hrt.82.3.269

Jia H, Abtahian F, Aguirre AD, Lee S, Chia S, Lowe H, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol. 2013;62(19):1748–58.

pubmed: 23810884 doi: 10.1016/j.jacc.2013.05.071

Ozaki Y, Okumura M, Ismail TF, Motoyama S, Naruse H, Hattori K, et al. Coronary CT angiographic characteristics of culprit lesions in acute coronary syndromes not related to plaque rupture as defined by optical coherence tomography and angioscopy. Eur Heart J. 2011;32(22):2814–23.

pubmed: 21719455 doi: 10.1093/eurheartj/ehr189

Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007;50(10):933–9.

pubmed: 17765119 doi: 10.1016/j.jacc.2007.04.082

Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet (Lond, Engl). 2017;389(10076):1312–22.

doi: 10.1016/S0140-6736(17)30057-0

Jolly SS, James S, Dzavik V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135(2):143–52.

pubmed: 27941066 doi: 10.1161/CIRCULATIONAHA.116.025371

Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557–67.

pubmed: 18256391 doi: 10.1056/NEJMoa0706416

Burzotta F, De Vita M, Gu YL, Isshiki T, Lefevre T, Kaltoft A, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. 2009;30(18):2193–203.

pubmed: 19726437 doi: 10.1093/eurheartj/ehp348

Ikari Y, Sakurada M, Kozuma K, Kawano S, Katsuki T, Kimura K, et al. Upfront thrombus aspiration in primary coronary intervention for patients with ST-segment elevation acute myocardial infarction: report of the VAMPIRE (VAcuuM asPIration thrombus REmoval) trial. JACC Cardiovasc Interv. 2008;1(4):424–31.

pubmed: 19463340 doi: 10.1016/j.jcin.2008.06.004

Nakatani D, Sato H, Sakata Y, Mizuno H, Shimizu M, Suna S, et al. Effect of intracoronary thrombectomy on 30-day mortality in patients with acute myocardial infarction. Am J Cardiol. 2007;100(8):1212–7.

pubmed: 17920359 doi: 10.1016/j.amjcard.2007.05.040

Hara H, Nakamura M, Komatsu H, Ikeda N, Shinji H, Makino K, et al. Comparison of the in vitro performance of 6 and 7 French aspiration catheters. EuroIntervention. 2007;2(4):487–92.

pubmed: 19755289

Anzai H, Yoneyama S, Tsukagoshi M, Miyake T, Kikuchi T, Sakurada M. Rescue percutaneous thrombectomy system provides better angiographic coronary flow and does not increase the in-hospital cost in patients with acute myocardial infarction. Circ J. 2003;67(9):768–74.

pubmed: 12939553 doi: 10.1253/circj.67.768

Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293(9):1063–72.

pubmed: 15741528 doi: 10.1001/jama.293.9.1063

Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J. 2008;29(24):2989–3001.

pubmed: 18812323 doi: 10.1093/eurheartj/ehn421

Isshiki T, Kozuma K, Kyono H, Suzuki N, Yokoyama N, Yamamoto Y. Initial clinical experience with distal embolic protection using “Filtrap”, a novel filter device with a self-expandable spiral basket in patients undergoing percutaneous coronary intervention. Cardiovasc Interv Ther. 2011;26(1):12–7.

pubmed: 24122493 doi: 10.1007/s12928-010-0027-y

Muramatsu T, Kozuma K, Tsukahara R, Ito Y, Fujita N, Suwa S, et al. Comparison of myocardial perfusion by distal protection before and after primary stenting for acute myocardial infarction: angiographic and clinical results of a randomized controlled trial. Catheter Cardiovasc Intervent. 2007;70(5):677–82.

doi: 10.1002/ccd.21190

Stone GW, Maehara A, Muller JE, Rizik DG, Shunk KA, Ben-Yehuda O, et al. Plaque characterization to inform the prediction and prevention of periprocedural myocardial infarction during percutaneous coronary intervention: the CANARY trial (coronary assessment by near-infrared of atherosclerotic rupture-prone yellow). JACC Cardiovasc Interv. 2015;8(7):927–36.

pubmed: 26003018 doi: 10.1016/j.jcin.2015.01.032

Hibi K, Kozuma K, Sonoda S, Endo T, Tanaka H, Kyono H, et al. Distal filter protection versus conventional treatment during PCI in patients with attenuated plaque identified by ivus: vacuum aspiration thrombus removal (VAMPIRE) 3 trial. Presented at TCT; 2017.

Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105(11):1285–90.

pubmed: 11901037 doi: 10.1161/01.CIR.0000012783.63093.0C

Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112(9):1284–8.

pubmed: 16116055 doi: 10.1161/CIRCULATIONAHA.104.530329

Miyazawa A, Ikari Y, Tanabe K, Nakajima H, Aoki J, Iijima R, et al. Intracoronary nicorandil prior to reperfusion in acute myocardial infarction. EuroIntervention. 2006;2(2):211–7.

pubmed: 19755263

Kobatake R, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels. 2011;26(4):379–84.

pubmed: 21110199 doi: 10.1007/s00380-010-0065-5

Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18(1):3.

pubmed: 29320987 pmcid: 5763527 doi: 10.1186/s12872-017-0722-z

Ndrepepa G, Kastrati A. Mechanical strategies to enhance myocardial salvage during primary percutaneous coronary intervention in patients with STEMI. EuroIntervention. 2016;12(3):319–28.

pubmed: 27320426 doi: 10.4244/EIJV12I3A52

Loubeyre C, Morice MC, Lefevre T, Piechaud JF, Louvard Y, Dumas P. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol. 2002;39(1):15–21.

pubmed: 11755281 doi: 10.1016/S0735-1097(01)01701-6

Mockel M, Vollert J, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, et al. Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. Am J Cardiol. 2011;108(12):1697–703.

pubmed: 21906709 doi: 10.1016/j.amjcard.2011.07.040

Dziewierz A, Siudak Z, Rakowski T, Kleczynski P, Zasada W, Dubiel JS, et al. Impact of direct stenting on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry). Catheter Cardiovasc Intervent. 2014;84(6):925–31.

doi: 10.1002/ccd.25266

Barbato E, Marco J, Wijns W. Direct stenting. Eur Heart J. 2003;24(5):394–403.

pubmed: 12633541 doi: 10.1016/S0195-668X(02)00802-3

Mintz GS. Remodeling and restenosis: observations from serial intravascular ultrasound studies. Curr Intervent Cardiol Rep. 2000;2(4):316–25.

Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001;88(3):297–301.

pubmed: 11472712 doi: 10.1016/S0002-9149(01)01645-9

De Luca G, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, Kastrati A, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 2008;126(1):37–44.

pubmed: 17544528 doi: 10.1016/j.ijcard.2007.03.112

Suryapranata H, De Luca G, van ’t Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart (Brit Card Soc). 2005;91(5):641–5.

doi: 10.1136/hrt.2004.056705

Saito S, Hosokawa G, Tanaka S, Nakamura S. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Intervent. 1999;48(3):262268.

doi: 10.1002/(SICI)1522-726X(199911)48:3<262::AID-CCD5>3.0.CO;2-4

Tsuchihashi M, Tsutsui H, Shihara M, Tada H, Kono S, Takeshita A. Comparison of outcomes for patients undergoing balloon angioplasty vs coronary stenting for acute myocardial infarction. Circ J. 2003;67(5):369–74.

pubmed: 12736471 doi: 10.1253/circj.67.369

Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355(11):1105–13.

pubmed: 16971717 doi: 10.1056/NEJMoa062598

Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28(22):2706–13.

pubmed: 17901079 doi: 10.1093/eurheartj/ehm402

De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol. 2009;133(2):213–22.

pubmed: 18394731 doi: 10.1016/j.ijcard.2007.12.040

Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation. 2003;108(22):2747–50.

pubmed: 14638542 doi: 10.1161/01.CIR.0000103666.25660.77

McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (Lond, Engl). 2004;364(9444):1519–21.

doi: 10.1016/S0140-6736(04)17275-9

Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118(11):1138–45.

pubmed: 18725485 doi: 10.1161/CIRCULATIONAHA.107.762047

Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (paclitaxel-eluting versus conventional stent in myocardial infarction with ST-segment elevation) trial. JACC Cardiovasc Interv. 2011;4(1):24–9.

pubmed: 21251625 doi: 10.1016/j.jcin.2010.11.003

Stone SG, Serrao GW, Mehran R, Tomey MI, Witzenbichler B, Guagliumi G, et al. Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. Circ Cardiovasc Interv. 2014;7(4):543–51.

pubmed: 24939928 doi: 10.1161/CIRCINTERVENTIONS.114.001360

Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv. 2009;2(5):445–52.

pubmed: 19463469 doi: 10.1016/j.jcin.2009.01.012

Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117(24):3152–6.

pubmed: 18559715 doi: 10.1161/CIRCULATIONAHA.107.742312

Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010;3(1):27–33.

pubmed: 20118156 doi: 10.1161/CIRCINTERVENTIONS.109.896225

Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013;111(2):178–84.

pubmed: 23111142 doi: 10.1016/j.amjcard.2012.09.015

Kelbaek H, Engstrom T, Ahtarovski KA, Lonborg J, Vejlstrup N, Pedersen F, et al. Deferred stent implantation in patients with ST-segment elevation myocardial infarction: a pilot study. EuroIntervention. 2013;8(10):1126–33.

pubmed: 23425538 doi: 10.4244/EIJV8I10A175

Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol. 2014;63(20):2088–98.

pubmed: 24583294 pmcid: 4029071 doi: 10.1016/j.jacc.2014.02.530

Kim JS, Lee HJ, Woong YuC, Kim YM, Hong SJ, Park JH, et al. INNOVATION Study (Impact of immediate stent implantation versus deferred stent implantation on infarct size and microvascular perfusion in patients with ST-segment-elevation myocardial infarction). Circ Cardiovasc Interv. 2016;9(12): e004101.

pubmed: 27965296 doi: 10.1161/CIRCINTERVENTIONS.116.004101

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62(6):496–504.

pubmed: 23747778 doi: 10.1016/j.jacc.2013.05.022

Philip F, Stewart S, Southard JA. Very late stent thrombosis with second generation drug eluting stents compared to bare-metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials. Catheter Cardiovasc Intervent. 2016;88(1):38–48.

doi: 10.1002/ccd.26458

Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink MA, Oh PC, et al. Efficacy and safety of stents in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2019;74(21):2572–84.

pubmed: 31753202 doi: 10.1016/j.jacc.2019.09.038

Brugaletta S, Gomez-Lara J, Ortega-Paz L, Jimenez-Diaz V, Jimenez M, Jiménez-Quevedo P, et al. 10-Year follow-up of patients with everolimus-eluting versus bare-metal stents after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(9):1165–78.

pubmed: 33663733 doi: 10.1016/j.jacc.2020.12.059

Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384(9960):2111–22.

pubmed: 25189359 doi: 10.1016/S0140-6736(14)61038-2

Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019;394(10205):1243–53.

pubmed: 31488372 doi: 10.1016/S0140-6736(19)31877-X

Iglesias JF, Roffi M, Losdat S, Muller O, Degrauwe S, Kurz DJ, et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. Lancet. 2023;402(10416):1979–90.

pubmed: 37898137 doi: 10.1016/S0140-6736(23)02197-9

Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–47.

pubmed: 26466021 doi: 10.1056/NEJMoa1503943

Naber CK, Urban P, Ong PJ, Valdes-Chavarri M, Abizaid AA, Pocock SJ, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a leaders free ACS substudy. Eur Heart J. 2017;38(13):961–9.

pubmed: 27190095

Jensen Lisette O, Maeng M, Raungaard B, Kahlert J, Ellert J, Jakobsen L, et al. Randomized comparison of the polymer-free biolimus-coated biofreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting orsiro stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX trial. Circulation. 2020;141(25):2052–63.

pubmed: 32434381 doi: 10.1161/CIRCULATIONAHA.119.040241

Sawada T, Shinke T, Otake H, Mizoguchi T, Iwasaki M, Emoto T, et al. Comparisons of detailed arterial healing response at seven months following implantation of an everolimus- or sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2013;168(2):960–6.

pubmed: 23164597 doi: 10.1016/j.ijcard.2012.10.043

Muramatsu T, Kozuma K, Tanabe K, Morino Y, Ako J, Nakamura S, et al. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther. 2023;38(2):166–76.

pubmed: 36847902 pmcid: 10020262 doi: 10.1007/s12928-023-00921-2

Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13(12):1391–402.

pubmed: 32473887 doi: 10.1016/j.jcin.2020.02.043

Vos NS, Dirksen MT, Vink MA, van Nooijen FC, Amoroso G, Herrman JP, et al. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in primary percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. EuroIntervention. 2014;10(5):584–90.

pubmed: 25256200 doi: 10.4244/EIJV10I5A101

Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial. JACC Cardiovasc Interv. 2019;12(17):1691–9.

pubmed: 31126887 doi: 10.1016/j.jcin.2019.04.016

Scheller B, Ohlow MA, Ewen S, Kische S, Rudolph TK, Clever YP, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2020;15(17):1527–33.

pubmed: 31659986 doi: 10.4244/EIJ-D-19-00723

Kuno T, Kiyohara Y, Maehara A, Ueyama HA, Kampaktsis PN, Takagi H, et al. Comparison of intravascular imaging, functional, or angiographically guided coronary intervention. J Am Coll Cardiol. 2023;82(23):2167–76.

pubmed: 37995152 doi: 10.1016/j.jacc.2023.09.823

Stone GW, Christiansen EH, Ali ZA, Andreasen LN, Maehara A, Ahmad Y, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. Lancet. 2024;403(10429):824–37.

pubmed: 38401549 doi: 10.1016/S0140-6736(23)02454-6

Giacoppo D, Laudani C, Occhipinti G, Spagnolo M, Greco A, Rochira C, et al. Coronary angiography, intravascular ultrasound, and optical coherence tomography for guiding of percutaneous coronary intervention: a systematic review and network meta-analysis. Circulation. 2024;149(14):1065–86.

pubmed: 38344859 pmcid: 10980178 doi: 10.1161/CIRCULATIONAHA.123.067583

Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, et al. Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in east Asian patients: 1-year results of the PENDULUM registry. J Am Heart Assoc. 2020;9(10): e015439.

pubmed: 32394794 pmcid: 7660889 doi: 10.1161/JAHA.119.015439

Hong SJ, Kim BK, Shin DH, Nam CM, Kim JS, Ko YG, et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JAMA. 2015;314(20):2155–63.

pubmed: 26556051 doi: 10.1001/jama.2015.15454

Hong SJ, Mintz GS, Ahn CM, Kim JS, Kim BK, Ko YG, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv. 2020;13(1):62–71.

pubmed: 31918944 doi: 10.1016/j.jcin.2019.09.033

Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll Cardiol. 2018;72(24):3126–37.

pubmed: 30261237 doi: 10.1016/j.jacc.2018.09.013

Gao XF, Ge Z, Kong XQ, Kan J, Han L, Lu S, et al. 3-Year Outcomes of the ULTIMATE trial comparing intravascular ultrasound versus angiography-guided drug-eluting stent implantation. JACC Cardiovasc Interv. 2021;14(3):247–57.

pubmed: 33541535 doi: 10.1016/j.jcin.2020.10.001

Li X, Ge Z, Kan J, Anjum M, Xie P, Chen X, et al. Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial. Lancet. 2024;403(10439):1855–65.

pubmed: 38604212 doi: 10.1016/S0140-6736(24)00282-4

Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024;403(10439):1866–78.

pubmed: 38599220 doi: 10.1016/S0140-6736(24)00473-2

Prati F, Di Vito L, Biondi-Zoccai G, Occhipinti M, La Manna A, Tamburino C, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l’Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention. 2012;8(7):823–9.

pubmed: 23034247 doi: 10.4244/EIJV8I7A125

Antonsen L, Thayssen P, Maehara A, Hansen HS, Junker A, Veien KT, et al. Optical coherence tomography guided percutaneous coronary intervention with nobori stent implantation in patients with non-ST-segment-elevation myocardial infarction (OCTACS) trial: difference in strut coverage and dynamic malapposition patterns at 6 months. Circ Cardiovasc Interv. 2015;8(8): e002446.

pubmed: 26253735 doi: 10.1161/CIRCINTERVENTIONS.114.002446

Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: results of the multicenter, randomized DOCTORS study (does optical coherence tomography optimize results of stenting). Circulation. 2016;134(13):906–17.

pubmed: 27573032 doi: 10.1161/CIRCULATIONAHA.116.024393

Kala P, Cervinka P, Jakl M, Kanovsky J, Kupec A, Spacek R, et al. OCT guidance during stent implantation in primary PCI: A randomized multicenter study with nine months of optical coherence tomography follow-up. Int J Cardiol. 2018;250:98–103.

pubmed: 29079414 doi: 10.1016/j.ijcard.2017.10.059

Jia H, Dai J, He L, Xu Y, Shi Y, Zhao L, et al. EROSION III: a multicenter RCT of OCT-guided reperfusion in STEMI with early infarct artery patency. JACC Cardiovasc Interv. 2022;15(8):846–56.

pubmed: 35367176 doi: 10.1016/j.jcin.2022.01.298

Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, et al. Optical coherence tomography-guided versus angiography-guided PCI. N Engl J Med. 2023;389(16):1466–76.

pubmed: 37634188 doi: 10.1056/NEJMoa2305861

Holm NR, Andreasen LN, Neghabat O, Laanmets P, Kumsars I, Bennett J, et al. OCT or angiography guidance for PCI in complex bifurcation lesions. N Engl J Med. 2023;389(16):1477–87.

pubmed: 37634149 doi: 10.1056/NEJMoa2307770

Lee JM, Choi KH, Song YB, Lee JY, Lee SJ, Lee SY, et al. Intravascular imaging-guided or angiography-guided complex PCI. N Engl J Med. 2023;388(18):1668–79.

pubmed: 36876735 doi: 10.1056/NEJMoa2216607

Ali ZA, Maehara A, Genereux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet. 2016;388(10060):2618–28.

pubmed: 27806900 doi: 10.1016/S0140-6736(16)31922-5

Chamie D, Costa JR Jr, Damiani LP, Siqueira D, Braga S, Costa R, et al. Optical coherence tomography versus intravascular ultrasound and angiography to guide percutaneous coronary interventions: the iSIGHT randomized trial. Circ Cardiovasc Interv. 2021;14(3): e009452.

pubmed: 33685212 doi: 10.1161/CIRCINTERVENTIONS.120.009452

de Feyter PJ, Ozaki Y, Baptista J, Escaned J, Di Mario C, de Jaegere PP, et al. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound. Circulation. 1995;92(6):1408–13.

pubmed: 7664420 doi: 10.1161/01.CIR.92.6.1408

Prati F, Uemura S, Souteyrand G, Virmani R, Motreff P, Di Vito L, et al. OCT-based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging. 2013;6(3):283–7.

pubmed: 23473109 doi: 10.1016/j.jcmg.2012.12.007

Jia H, Dai J, Hou J, Xing L, Ma L, Liu H, et al. Effective antithrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J. 2017;38(11):792–800.

pubmed: 27578806

Prati F, Romagnoli E, Gatto L, La Manna A, Burzotta F, Ozaki Y, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. Eur Heart J. 2020;41(3):383–91.

pubmed: 31504405 doi: 10.1093/eurheartj/ehz520

Madder RD, Goldstein JA, Madden SP, Puri R, Wolski K, Hendricks M, et al. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2013;6(8):838–46.

pubmed: 23871513 doi: 10.1016/j.jcin.2013.04.012

Madder RD, Puri R, Muller JE, Harnek J, Gotberg M, VanOosterhout S, et al. Confirmation of the intracoronary near-infrared spectroscopy threshold of lipid-rich plaques that underlie ST-segment-elevation myocardial infarction. Arterioscler Thromb Vasc Biol. 2016;36(5):1010–5.

pubmed: 26941016 doi: 10.1161/ATVBAHA.115.306849

Madder RD, Husaini M, Davis AT, Van Oosterhout S, Harnek J, Gotberg M, et al. Detection by near-infrared spectroscopy of large lipid cores at culprit sites in patients with non-ST-segment elevation myocardial infarction and unstable angina. Catheter Cardiovasc Interv. 2014;86(6):1014–21.

pubmed: 25418711 doi: 10.1002/ccd.25754

Kini AS, Motoyama S, Vengrenyuk Y, Feig JE, Pena J, Baber U, et al. Multimodality intravascular imaging to predict periprocedural myocardial infarction during percutaneous coronary intervention. JACC Cardiovasc Interv. 2015;8(7):937–45.

pubmed: 26088511 doi: 10.1016/j.jcin.2015.03.016

Ozaki Y, Ohota M, Ismail TF, Okumura M, Ishikawa M, Muramatsu T. Thin cap fibroatheroma defined as lipid core abutting lumen (LCAL) on integrated backscatter intravascular ultrasound—comparison with optical coherence tomography and correlation with periprocedural myocardial infarction. Circ J. 2015;79(4):808–17.

pubmed: 25740668 doi: 10.1253/circj.CJ-14-0758

Raber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018;39(35):3281–300.

pubmed: 29790954 doi: 10.1093/eurheartj/ehy285

Prati F, Romagnoli E, Burzotta F, Limbruno U, Gatto L, La Manna A, et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. JACC Cardiovasc Imaging. 2015;8(11):1297–305.

pubmed: 26563859 doi: 10.1016/j.jcmg.2015.08.013

Prati F, Romagnoli E, Gatto L, La Manna A, Burzotta F, Limbruno U, et al. Clinical impact of suboptimal stenting and residual intrastent plaque/thrombus protrusion in patients with acute coronary syndrome: the CLI-OPCI ACS substudy (Centro per la Lotta Contro L’Infarto-Optimization of Percutaneous Coronary Intervention in Acute Coronary Syndrome). Circ Cardiovasc Interv. 2016;9(12): e003726.

pubmed: 27965297 doi: 10.1161/CIRCINTERVENTIONS.115.003726

Kubo T, Shinke T, Okamura T, Hibi K, Nakazawa G, Morino Y, et al. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results. Eur Heart J. 2017;38(42):3139–47.

pubmed: 29121226 pmcid: 5837511 doi: 10.1093/eurheartj/ehx351

Radu MD, Raber L, Heo J, Gogas BD, Jorgensen E, Kelbaek H, et al. Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation. EuroIntervention. 2014;9(9):1085–94.

pubmed: 24064426 doi: 10.4244/EIJV9I9A183

De Cock D, Bennett J, Ughi GJ, Dubois C, Sinnaeve P, Dhooge J, et al. Healing course of acute vessel wall injury after drug-eluting stent implantation assessed by optical coherence tomography. Eur Heart J Cardiovasc Imaging. 2014;15(7):800–9.

pubmed: 24497520 doi: 10.1093/ehjci/jeu003

Bouki KP, Sakkali E, Toutouzas K, Vlad D, Barmperis D, Phychari S, et al. Impact of coronary artery stent edge dissections on long-term clinical outcome in patients with acute coronary syndrome: an optical coherence tomography study. Catheter Cardiovasc Intervent. 2015;86(2):237–46.

doi: 10.1002/ccd.25855

Chamie D, Bezerra HG, Attizzani GF, Yamamoto H, Kanaya T, Stefano GT, et al. Incidence, predictors, morphological characteristics, and clinical outcomes of stent edge dissections detected by optical coherence tomography. JACC Cardiovasc Interv. 2013;6(8):800–13.

pubmed: 23871510 doi: 10.1016/j.jcin.2013.03.019

Kawamori H, Shite J, Shinke T, Otake H, Matsumoto D, Nakagawa M, et al. Natural consequence of post-intervention stent malapposition, thrombus, tissue prolapse, and dissection assessed by optical coherence tomography at mid-term follow-up. Eur Heart J Cardiovasc Imaging. 2013;14(9):865–75.

pubmed: 23291393 pmcid: 3738096 doi: 10.1093/ehjci/jes299

Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM, Yamaji K, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation. 2016;133(7):650–60.

pubmed: 26762519 doi: 10.1161/CIRCULATIONAHA.115.019071

Steinberg DH, Mintz GS, Mandinov L, Yu A, Ellis SG, Grube E, et al. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies. JACC Cardiovasc Interv. 2010;3(5):486–94.

pubmed: 20488404 doi: 10.1016/j.jcin.2010.03.007

Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, et al. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial. Circulation. 2010;122(11):1077–84.

pubmed: 20805433 doi: 10.1161/CIRCULATIONAHA.109.906040

Romagnoli E, Gatto L, La Manna A, Burzotta F, Taglieri N, Saia F, et al. Role of residual acute stent malapposition in percutaneous coronary interventions. Catheter Cardiovasc Intervent. 2017;90(4):566–78.

doi: 10.1002/ccd.26974

Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur Heart J. 2010;31(12):1470–6.

pubmed: 20363765 doi: 10.1093/eurheartj/ehq066

Kim H, Ahn J-M, Kang D-Y, Lee J, Choi Y, Park S-J, et al. Management of coronary vulnerable plaque with medical therapy or local preventive percutaneous coronary intervention. JACC ASIA. 2024;4(6):425–43.

pubmed: 39100699 pmcid: 11291350 doi: 10.1016/j.jacasi.2024.04.001

Tomaniak M, Katagiri Y, Modolo R, de Silva R, Khamis RY, Bourantas CV, et al. Vulnerable plaques and patients: state-of-the-art. Eur Heart J. 2020;41(31):2997–3004.

pubmed: 32402086 pmcid: 8453282 doi: 10.1093/eurheartj/ehaa227

Kedhi E, Berta B, Roleder T, Hermanides RS, Fabris E, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur Heart J. 2021;42(45):4671–9.

pubmed: 34345911 doi: 10.1093/eurheartj/ehab433

Mol JQ, Volleberg R, Belkacemi A, Hermanides RS, Meuwissen M, Protopopov AV, et al. Fractional flow reserve-negative high-risk plaques and clinical outcomes after myocardial infarction. JAMA Cardiol. 2023;8(11):1013–21.

pubmed: 37703036 pmcid: 10500430 doi: 10.1001/jamacardio.2023.2910

Park SJ, Ahn JM, Kang DY, Yun SC, Ahn YK, Kim WJ, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403(10438):1753–65.

pubmed: 38604213 doi: 10.1016/S0140-6736(24)00413-6

Carrick D, Haig C, Carberry J, May VTY, McCartney P, Welsh P, et al. Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. JCI Insight. 2016;1(6): e85768.

pubmed: 27699259 pmcid: 5033815 doi: 10.1172/jci.insight.85768

Murai T, Yonetsu T, Kanaji Y, Usui E, Hoshino M, Hada M, et al. Prognostic value of the index of microcirculatory resistance after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome. Catheter Cardiovasc Interv. 2018;92(6):1063–74.

pubmed: 29446567 doi: 10.1002/ccd.27529

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287–96.

pubmed: 22920912 doi: 10.1056/NEJMoa1208410

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet (Lond, Engl). 2013;382(9905):1638–45.

doi: 10.1016/S0140-6736(13)61783-3

Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011;306(12):1329–37.

pubmed: 21878431 doi: 10.1001/jama.2011.1280

Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83(5):1085–196.

pubmed: 30930428 doi: 10.1253/circj.CJ-19-0133

Nishimoto Y, Ohbe H, Matsui H, Nakata J, Takiguchi T, Nakajima M, et al. Trends in mechanical circulatory support use and outcomes of patients with cardiogenic shock in Japan, 2010 to 2020 (from a Nationwide Inpatient Database Study). Am J Cardiol. 2023;203:203–11.

pubmed: 37499600 doi: 10.1016/j.amjcard.2023.06.082

Nishimoto Y, Inohara T, Kohsaka S, Sakakura K, Kawai T, Kikuchi A, et al. Changing trends in mechanical circulatory support use and outcomes in patients undergoing percutaneous coronary interventions for acute coronary syndrome complicated with cardiogenic shock: insights from a nationwide registry in Japan. J Am Heart Assoc. 2023;12(23): e031838.

pubmed: 38038195 pmcid: 10727314 doi: 10.1161/JAHA.123.031838

Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584–8.

pubmed: 19007597 doi: 10.1016/j.jacc.2008.05.065

Basir MB, Lemor A, Gorgis S, Patel KC, Kolski BC, Bharadwaj AS, et al. Early utilization of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: the national cardiogenic shock initiative. J Am Heart Assoc. 2023;12(23): e031401.

pubmed: 38014676 pmcid: 10727311 doi: 10.1161/JAHA.123.031401

Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(3):278–87.

pubmed: 27810347 doi: 10.1016/j.jacc.2016.10.022

Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139(10):1249–58.

pubmed: 30586755 doi: 10.1161/CIRCULATIONAHA.118.036614

Kapur NK, Kim RJ, Moses JW, Stone GW, Udelson JE, Ben-Yehuda O, et al. Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: rationale and design of the STEMI-DTU randomized pivotal trial. Am Heart J. 2022;254:122–32.

pubmed: 36058253 doi: 10.1016/j.ahj.2022.08.011

Delmas C, Laine M, Schurtz G, Roubille F, Coste P, Leurent G, et al. Rationale and design of the ULYSS trial: a randomized multicenter evaluation of the efficacy of early impella CP implantation in acute coronary syndrome complicated by cardiogenic shock. Am Heart J. 2023;265:203–12.

pubmed: 37657594 doi: 10.1016/j.ahj.2023.08.066

Aso S, Matsui H, Fushimi K, Yasunaga H. The effect of intra-aortic balloon pumping under venoarterial extracorporeal membrane oxygenation on mortality of cardiogenic patients: an analysis using a nationwide inpatient database. Crit Care Med. 2016;44(11):1974–9.

pubmed: 27322361 doi: 10.1097/CCM.0000000000001828

Saito Y, Tateishi K, Toda K, Matsumiya G, Kobayashi Y, JPrsinvestigators. Complications and outcomes of impella treatment in cardiogenic shock patients with and without acute myocardial infarction. J Am Heart Assoc. 2023;12(17): e030819.

pubmed: 37646217 pmcid: 10547360 doi: 10.1161/JAHA.123.030819

Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LS, van Domburg RT, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30(17):2102–8.

pubmed: 19617601 doi: 10.1093/eurheartj/ehp292

Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, et al. Results of the post-U.S. food and drug administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (interagency registry for mechanically assisted circulatory support). J Am Coll Cardiol. 2011;57(19):1890–8.

pubmed: 21545946 doi: 10.1016/j.jacc.2010.10.062

Sheu JJ, Tsai TH, Lee FY, Fang HY, Sun CK, Leu S, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med. 2010;38(9):1810–7.

pubmed: 20543669 doi: 10.1097/CCM.0b013e3181e8acf7

Atkinson TM, Ohman EM, O’Neill WW, Rab T, Cigarroa JE. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention: an interventional perspective. JACC Cardiovasc Interv. 2016;9(9):871–83.

pubmed: 27151604 doi: 10.1016/j.jcin.2016.02.046

Cubeddu RJ, Lago R, Horvath SA, Vignola PA, O’Neill W, Palacios IF. Use of the Impella 2.5 system alone, after and in combination with an intra-aortic balloon pump in patients with cardiogenic shock: case description and review of the literature. EuroIntervention. 2012;7(12):1453–60.

pubmed: 22522555 doi: 10.4244/EIJV7I12A226

Wiktor DM, Sawlani N, Kanthi Y, Sipahi I, Fang JC, Blitz A. Successful combined use of Impella Recover 2.5 device and intra-aortic balloon pump support in cardiogenic shock from acute myocardial infarction. ASAIO J. 2010;56(6):519–21.

pubmed: 20938341 doi: 10.1097/MAT.0b013e3181f7478e

Burzotta F, Trani C, Doshi SN, Townend J, van Geuns RJ, Hunziker P, et al. Impella ventricular support in clinical practice: collaborative viewpoint from a European expert user group. Int J Cardiol. 2015;201:684–91.

pubmed: 26363632 doi: 10.1016/j.ijcard.2015.07.065

Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet (Lond, Engl). 2017;389(10073):1025–34.

doi: 10.1016/S0140-6736(17)30397-5

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;39(3):213–60.

doi: 10.1093/eurheartj/ehx419

Yoshikawa Y, Shiomi H, Watanabe H, Natsuaki M, Kondo H, Tamura T, et al. Validating utility of dual antiplatelet therapy score in a large pooled cohort from 3 Japanese percutaneous coronary intervention studies. Circulation. 2018;137(6):551–62.

pubmed: 28982692 doi: 10.1161/CIRCULATIONAHA.117.028924

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J. 2019;40(31):2632–53.

pubmed: 31116395 pmcid: 6736433 doi: 10.1093/eurheartj/ehz372

Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, et al. Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention. Circ Cardiovasc Interv. 2019;12(11): e008307.

pubmed: 31707804 doi: 10.1161/CIRCINTERVENTIONS.119.008307

Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84(5):831–65.

pubmed: 32173684 doi: 10.1253/circj.CJ-19-1109

Natsuaki M, Morimoto T, Shiomi H, Ehara N, Taniguchi R, Tamura T, et al. Application of the modified high bleeding risk criteria for Japanese patients in an all-comers registry of percutaneous coronary intervention—from the CREDO-Kyoto registry cohort-3. Circ J. 2021;85(6):769–81.

pubmed: 33298644 doi: 10.1253/circj.CJ-20-0836

Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–9.

pubmed: 30166073 doi: 10.1016/S0140-6736(18)31858-0

Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS Trial. JAMA Cardiol. 2019;4(11):1092–101.

pubmed: 31557763 pmcid: 6764000 doi: 10.1001/jamacardio.2019.3355

Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–37.

pubmed: 31237645 pmcid: 6593635 doi: 10.1001/jama.2019.8146

Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–42.

pubmed: 31556978 doi: 10.1056/NEJMoa1908419

Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020;41(37):3533–45.

pubmed: 33085967 doi: 10.1093/eurheartj/ehaa670

Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407–16.

pubmed: 32543684 pmcid: 7298605 doi: 10.1001/jama.2020.7580

Lee SJ, Cho JY, Kim BK, Yun KH, Suh Y, Cho YH, et al. Ticagrelor monotherapy versus ticagrelor with aspirin in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2021;14(4):431–40.

pubmed: 33602439 doi: 10.1016/j.jcin.2020.11.036

Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385(18):1643–55.

pubmed: 34449185 doi: 10.1056/NEJMoa2108749

Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial. Circulation. 2021;144(15):1196–211.

pubmed: 34455849 pmcid: 8500374 doi: 10.1161/CIRCULATIONAHA.121.056680

Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272–7.

pubmed: 21081908 doi: 10.1038/ajg.2010.436

Uchiyama S, Goto S, Origasa H, Uemura N, Sugano K, Hiraishi H, et al. Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the management of aspirin-induced gastrointestinal complications (MAGIC) study. Heart Vessels. 2020;35(2):170–6.

pubmed: 31446462 doi: 10.1007/s00380-019-01484-0

Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, et al. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol. 2014;49(5):814–24.

pubmed: 23754512 doi: 10.1007/s00535-013-0839-5

Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–27.

pubmed: 31237644 pmcid: 6593641 doi: 10.1001/jama.2019.8145

Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022;7(4):407–17.

pubmed: 35234821 pmcid: 8892373 doi: 10.1001/jamacardio.2021.5244

Obayashi Y, Watanabe H, Morimoto T, Yamamoto K, Natsuaki M, Domei T, et al. Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort. Circ Cardiovasc Interv. 2022;15(8): e012004.

pubmed: 35912647 pmcid: 9371064 doi: 10.1161/CIRCINTERVENTIONS.122.012004

Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, et al. Clopidogrel vs aspirin monotherapy beyond 1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2024;83(1):17–31.

pubmed: 37879491 doi: 10.1016/j.jacc.2023.10.013

Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, et al. P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82(2):89–105.

pubmed: 37407118 doi: 10.1016/j.jacc.2023.04.051

Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.

pubmed: 27959713 doi: 10.1056/NEJMoa1611594

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.

pubmed: 28844193 doi: 10.1056/NEJMoa1708454

Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.

pubmed: 30883055 doi: 10.1056/NEJMoa1817083

Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF-PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–43.

pubmed: 31492505 doi: 10.1016/S0140-6736(19)31872-0

Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40(46):3757–67.

pubmed: 31651946 doi: 10.1093/eurheartj/ehz732

Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–13.

pubmed: 31475793 doi: 10.1056/NEJMoa1904143

Ozaki Y, Kawai H, Muramatsu T, Harada M, Takahashi H, Ishii H, et al. Rationale and design of rivaroxaban estimation with warfarin in atrial fibrillation patients with coronary stent implantation (REWRAPS). Circ Rep. 2022;4(12):604–8.

pubmed: 36530841 pmcid: 9726694 doi: 10.1253/circrep.CR-22-0096

Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381(15):1411–21.

pubmed: 31475795 doi: 10.1056/NEJMoa1907775

Bainey KR, Engstrøm T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. JAMA Cardiol. 2020;5(8):1–9.

pmcid: 7240651 doi: 10.1001/jamacardio.2020.1251

Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386(9994):665–71.

pubmed: 26347918 doi: 10.1016/S0140-6736(15)60648-1

Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376(13):1234–44.

pubmed: 28317428 doi: 10.1056/NEJMoa1701067

Smits PC, Laforgia PL, Abdel-Wahab M, Neumann FJ, Richardt G, Boxma-de Klerk B, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the compare-acute trial. EuroIntervention. 2020;16(3):225–32.

pubmed: 32250250 doi: 10.4244/EIJ-D-20-00012

Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, et al. Complete or culprit-only PCI in older patients with myocardial infarction. N Engl J Med. 2023;389(10):889–98.

pubmed: 37634150 doi: 10.1056/NEJMoa2300468

Bohm F, Mogensen B, Engstrom T, Stankovic G, Srdanovic I, Lonborg J, et al. FFR-guided complete or culprit-only PCI in patients with myocardial infarction. N Engl J Med. 2024;390(16):1481–92.

pubmed: 38587995 doi: 10.1056/NEJMoa2314149

Rioufol G, Derimay F, Roubille F, Perret T, Motreff P, Angoulvant D, et al. Fractional flow reserve to guide treatment of patients with multivessel coronary artery disease. J Am Coll Cardiol. 2021;78(19):1875–85.

pubmed: 34736563 doi: 10.1016/j.jacc.2021.08.061

Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. Multivessel PCI guided by FFR or angiography for myocardial infarction. N Engl J Med. 2021;385(4):297–308.

pubmed: 33999545 doi: 10.1056/NEJMoa2104650

Lee JM, Kim HK, Park KH, Choo EH, Kim CJ, Lee SH, et al. Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial. Eur Heart J. 2023;44(6):473–84.

pubmed: 36540034 doi: 10.1093/eurheartj/ehac763

Barauskas M, Ziubryte G, Jodka N, Unikas R. Quantitative flow ratio vs. angiography-only guided PCI in STEMI patients: one-year cardiovascular outcomes. BMC Cardiovasc Disord. 2023;23(1):136.

pubmed: 36918808 pmcid: 10015917 doi: 10.1186/s12872-023-03153-7

Diletti R, den Dekker WK, Bennett J, Schotborgh CE, van der Schaaf R, Sabate M, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401(10383):1172–82.

pubmed: 36889333 doi: 10.1016/S0140-6736(23)00351-3

Stahli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, et al. Timing of complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2023;389(15):1368–79.

pubmed: 37634190 doi: 10.1056/NEJMoa2307823

Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus culprit-only lesion intervention in patients with acute coronary syndromes. J Am Coll Cardiol. 2018;72(17):1989–99.

pubmed: 30336821 doi: 10.1016/j.jacc.2018.07.089

Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J. 2015;36(2):100–11.

pubmed: 25179764 doi: 10.1093/eurheartj/ehu338

Elscot JJ, Kakar H, Scarparo P, den Dekker WK, Bennett J, Schotborgh CE, et al. Timing of complete multivessel revascularization in patients presenting with non-ST-segment elevation acute coronary syndrome. JACC Cardiovasc Interv. 2024;17(6):771–82.

pubmed: 38538172 doi: 10.1016/j.jcin.2024.01.278

Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. New Engl J Med. 2017;377(25):2419–32.

pubmed: 29083953 doi: 10.1056/NEJMoa1710261

Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, et al. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379(18):1699–710.

pubmed: 30145971 doi: 10.1056/NEJMoa1808788

Choi KH, Yang JH, Park TK, Lee JM, Song YB, Hahn JY, et al. Culprit-only versus immediate multivessel percutaneous coronary intervention in patients with acute myocardial infarction complicating advanced cardiogenic shock requiring venoarterial-extracorporeal membrane oxygenation. J Am Heart Assoc. 2023;12(10): e029792.

pubmed: 37158104 pmcid: 10227301 doi: 10.1161/JAHA.123.029792

Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143–53.

pubmed: 28158518

Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139(18):e891–908.

pubmed: 30913893 doi: 10.1161/CIR.0000000000000670

Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, et al. JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. Circ J. 2023;87(6):879–936.

pubmed: 36908169 doi: 10.1253/circj.CJ-22-0779

Takahashi J, Onuma S, Hao K, Godo S, Shiroto T, Yasuda S. Pathophysiology and diagnostic pathway of myocardial infarction with non-obstructive coronary arteries. J Cardiol. 2024;83(1):17–24.

pubmed: 37524299 doi: 10.1016/j.jjcc.2023.07.014

Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and non-obstructive coronary arteries. Circulation. 2015;131(10):861–70.

pubmed: 25587100 doi: 10.1161/CIRCULATIONAHA.114.011201

CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Classifications MeSH